Synta Pharmaceuticals Corp. ended 2008 on a high note, inking a potentially lucrative early stage deal with F. Hoffmann-La Roche Ltd. for up to three compounds targeting calcium release-activated calcium (CRAC) modulator channels for treating inflammatory diseases. (BioWorld Today) Read More